We are pleased to announce the appointment of Gabriella Gentile as Chief Operating Officer (COO) at Symeres. With more than 25 years of international experience in the pharmaceutical, medical device, and services sectors, Gabriella brings a proven track record in operational performance, lean methodologies, and global transformation programs.
In her new role, Gabriella will lead the transformation of Symeres’ global operations, supporting growth across the pharmaceutical value chain, from drug discovery and development through IND-enabling studies. Her leadership will further strengthen our transatlantic expansion and reinforce Symeres’ commitment to quality, innovation, and customer satisfaction.
“I’m delighted to join Symeres at this exciting time in their growth. Symeres operates under a cultural philosophy of openness and transparency, and I look forward to being part of developing next-generation therapies,”
said Gabriella Gentile.
Symeres CEO Guillaume Jetten added:
“Gabriella brings a set of highly relevant skills and experience from both her background in medicinal chemistry, and her decades of large pharma and biotech experience that will support the future growth plans of Symeres.”
This appointment marks another significant step in our mission to strengthen Symeres’ position as a leading global CRDMO, bridging European innovation with American market presence and helping biotech and pharma partners in bringing new therapies to patients.
